Parallel progression of primary tumours and metastases

Nature Reviews Cancer

Volumn 9, Issue 4, 2009, Pages 302-312

  Klein, Christoph A ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TRASTUZUMAB;

AUTOPSY; CLINICAL TRIAL; DISEASE COURSE; GENETIC ANALYSIS; GROWTH RATE; HUMAN; METASTASIS; MOLECULAR GENETICS; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; STATISTICAL MODEL; TUMOR CELL; TUMOR GROWTH;

DISEASE PROGRESSION; HUMANS; MODELS, THEORETICAL; NEOPLASM METASTASIS; NEOPLASMS;

EID: 63049102497     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2627     Document Type: Review

References (97)

1. Jemal, A. et al. Cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96 (2008).
2. Arteaga, C. L. & Baselga, J. Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? Cancer Cell 5, 525-531 (2004).
3. Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005).
4. Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673-1684 (2005).
5. Weinstein, I. B. & Joe, A. K. Mechanisms of disease: Oncogene addiction - a rationale for molecular targeting in cancer therapy. Nature Clin. Pract Oncol. 3, 448-457 (2006).
6. Klein, G. Foulds' dangerous idea revisited: the multistep development of tumors 40 years later. Adv. Cancer Res. 72, 1-23 (1998).
7. Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759-767 (1990).
8. Cairns, J. Mutation selection and the natural history of cancer. Nature 255, 197-200 (1975).
9. Olivier, M. et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin. Cancer Res. 12, 1157-1167 (2006).
10. Weinberg, R. A. The many faces of tumor dormancy. APMIS 116, 548-551 (2008).
11. Bross, I. D., Viadana, E. & Pickren, J. Do generalized metastases occur directly from the primary? J. Chronic Dis. 28, 149-159 (1975).
12. Weinberg, R. A. Mechanisms of malignant progression. Carcinogenesis 29, 1092-1095 (2008).
13. Collins, V. P., Loeffler, R. K. & Tivey, H. Observations on growth rates of human tumors. Am. J. Roentgenol. Radium Ther. Nucl. Med. 76, 988-1000 (1956).
14. Friberg, S. & Mattson, S. On the growth rates of human malignant tumors: implications for medical decision making. J. Surg. Oncol. 65, 284-297 (1997).
15. Greene, F. L. & Sobin, L. H. The staging of cancer: a retrospective and prospective appraisal. CA Cancer J. Clin. 58, 180-190 (2008).
16. Loberg, R. D., Bradley, D. A., Tomlins, S. A., Chinnaiyan, A. M. & Pienta, K. J. The lethal phenotype of cancer: the molecular basis of death due to malignancy. CA Cancer J. Clin. 57, 225-241 (2007).
17. Spratt, J. S., Meyer, J. S. & Spratt, J. A. Rates of growth of human neoplasms: Part II. J. Surg. Oncol. 61, 68-83 (1996).
18. Spratt, J. S. Jr & Spratt, T. L. Rates of growth of pulmonary metastases and host survival. Ann. Surg. 159, 161-171 (1964).
19. Kusama, S., Spratt, J. S. Jr, Donegan, W. L., Watson, F. R. & Cunningham, C. The gross rates of growth of human mammary carcinoma. Cancer 30, 594-599 (1972).
20. Finlay, I. G., Meek, D., Brunton, F. & McArdle, C. S. Growth rate of hepatic metastases in colorectal carcinoma. Br. J. Surg. 75, 641-644 (1988).
21. Peer, P. G., van Dijck, J. A., Hendriks, J. H., Holland, R. & Verbeek, A. L. Age-dependent growth rate of primary breast cancer. Cancer 71, 3547-3551 (1993).
22. Engel, J. et al. The process of metastasisation for breast cancer. Eur. J. Cancer 39, 1794-1806 (2003).
23. Holzel, D., Eckel, R. & Engel, J. Metastasierung beim kolorektalen Karzinom: Häufigkeiten, Prognose und Folgerungen. Chirurg. 28 Sep 2008 [epub ahead of print] (in German).
24. Abbruzzese, J. L. et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J. Clin. Oncol. 12, 1272-1280 (1994).
25. van de Wouw, A. J., Janssen-Heijnen, M. L., Coebergh, J. W. & Hillen, H. F. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992 Eur. J. Cancer 38, 409-413 (2002).
26. Kaplan, R. N. et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820-827 (2005).
27. McAllister, S. S. et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 133, 994-1005 (2008).
28. Taniguchi, T. et al. Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin. Cancer Res. 1, 1031-1034 (1995).
29. Schlimok, G. et al. Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc. Natl Acad. Sci. USA 84, 8672-8676 (1987).
30. Klein, C. A. The systemic progression of human cancer: a focus on the individual disseminated cancer cell - the unit of selection. Adv. Cancer Res. 89, 35-67 (2003).
31. Pantel, K., Cote, R. J. & Fodstad, O. Detection and clinical importance of micrometastatic disease. J. Natl Cancer Inst. 91, 1113-1124 (1999).
32. Fehm, T. et al. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 107, 885-892 (2006).
33. Riethdorf, S., Wikman, H. & Pantel, K. Biological relevance of disseminated tumor cells in cancer patients. Int. J. Cancer 123, 1991-2006 (2008).
34. Klein, C. A. et al. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc. Natl Acad. Sci. USA 96, 4494-4499 (1999).
35. Klein, C. A. et al. Combined transcriptome and genome analysis of single micrometastatic cells. Nature Biotechnol. 20, 387-392 (2002).
36. Schardt, J. A. et al. Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell 8, 227-239 (2005).
37. Schmidt-Kittler, O. et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc. Natl Acad. Sci. USA 100, 7737-7742 (2003).
38. Stoecklein, N. H. et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 13, 441-453 (2008).
39. Weckermann, D. et al. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J. Clin. Oncol. 23 Feb 2009 (doi:10.1200/JCO.2008.17.0563).
40. Klein, C. A. et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360, 683-689 (2002).
41. Albanese, I. et al. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem. Biophys. Res. Commun. 325, 784-791 (2004).
42. Artale, S. et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J. Clin. Oncol. 26, 4217-4219 (2008).
43. Oudejans, J. J., Slebos, R. J., Zoetmulder, F. A., Mooi, W. J. & Rodenhuis, S. Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int. J. Cancer 49, 875-879 (1991).
44. Badalian, G. et al. Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS mutational status. Pathol. Oncol. Res. 13, 99-104 (2007).
45. Kalikaki, A. et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br. J. Cancer 99, 923-929 (2008).
46. Gow, C. H. et al. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann. Oncol. 16 Dec 2008 (doi:10.1093/annonc/mdn679).
47. Becker, T. E. et al. The genomic heritage of lymph node metastases: implications for clinical management of patients with breast cancer. Ann. Surg. Oncol. 15, 1056-1063 (2008).
48. Bissig, H. et al. Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization. Am. J. Pathol. 155, 267-274 (1999).
49. Kuukasjarvi, T. et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res. 57, 1597-1604 (1997).
50. Katona, T. M. et al. Genetically heterogeneous and clonally unrelated metastases may arise in patients with cutaneous melanoma. Am. J. Surg. Pathol. 31, 1029-1037 (2007).
51. Jones, S. et al. Comparative lesion sequencing provides insights into tumor evolution. Proc. Natl Acad. Sci. USA 105, 4283-4288 (2008).
52. Weigelt, B. et al. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc. Natl Acad. Sci. USA 100, 15901-15905 (2003).
53. Hunter, K. Host genetics influence tumour metastasis. Nature Rev. Cancer 6, 141-146 (2006).
54. Husemann, Y. et al. Systemic spread is an early step in breast cancer. Cancer Cell 13, 58-68 (2008).
55. Zhao, L. & Vogt, P. K. Class I PI3K in oncogenic cellular transformation. Oncogene 27, 5486-5496 (2008).
56. Baudis, M. Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data. BMC Cancer 7, 226 (2007).
57. Fidler, I. J. Selection of successive tumour lines for metastasis. Nat. New Biol. 242, 148-149 (1973).
58. Viadana, E., Cotter, R., Pickren, J. W. & Bross, I. D. An autopsy study of metastatic sites of breast cancer. Cancer Res. 33, 179-181 (1973).
59. Weiss, L. et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J. Pathol. 150, 195-203 (1986).
60. Weiss, L. et al. Metastatic patterns of renal carcinoma: an analysis of 687 necropsies. J. Cancer Res. Clin. Oncol. 114, 605-612 (1988).
61. Klein, C. A. & Holzel, D. Systemic cancer progression and tumor dormancy: mathematical models meet single cell genomics. Cell Cycle 5, 1788-1798 (2006).
62. Halsted, W. S. I. The results of radical operations for the cure of carcinoma of the breast. Ann. Surg. 46, 1-19 (1907).
63. Fisher, B. et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N. Engl. J. Med. 347, 567-575 (2002).
64. Rudenstam, C. M. et al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93 J. Clin. Oncol. 24, 337-344 (2006).
65. Veronesi, U., Marubini, E., Mariani, L., Valagussa, P. & Zucali, R. The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial. Eur. J. Cancer 35, 1320-1325 (1999).
66. Kitchener, H., Swart, A. M., Qian, Q., Amos, C. & Parmar, M. K. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373, 125-136 (2009).
67. Stemmler, H. J. et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 18, 23-28 (2007).
68. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
69. Joensuu, H. et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354, 809-820 (2006).
70. Lin, N. U. & Winer, E. P. Brain metastases: the HER2 paradigm. Clin. Cancer Res. 13, 1648-1655 (2007).
71. Ulmer, A. et al. Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells. Clin. Cancer Res. 10, 531-537 (2004).
72. Cristofanilli, M. et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351, 781-791 (2004).
73. Dawood, S. et al. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer 113, 2422-2430 (2008).
74. Maheswaran, S. et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359, 366-377 (2008).
75. Scheel, C., Onder, T., Karnoub, A. & Weinberg, R. A. Adaptation versus selection: the origins of metastatic behavior. Cancer Res. 67, 11476-11479; discussion 11479-80 (2007).
76. Kang, Y. et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549 (2003).
77. Brabletz, T., Jung, A., Spaderna, S., Hlubek, F. & Kirchner, T. Migrating cancer stem cells - an integrated concept of malignant tumour progression. Nature Rev. Cancer 5, 744-749 (2005).
78. Visvader, J. E. & Lindeman, G. J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature Rev. Cancer 8, 755-768 (2008).
79. Quintana, E. et al. Efficient tumour formation by single human melanoma cells. Nature 456, 593-598 (2008).
80. Fiegler, H. et al. High resolution array-CGH analysis of single cells. Nucleic Acids Res. 35, e15 (2007).
81. Fuhrmann, C. et al. High-resolution array comparative genomic hybridization of single micrometastatic tumor cells. Nucleic Acids Res. 36, e39 (2008).
82. Klein, C. A. The direct molecular analysis of metastatic precursor cells in breast cancer: A chance for a better understanding of metastasis and for personalised medicine. Eur. J. Cancer 44, 2721-2725 (2008).
83. Pantel, K. & Brakenhoff, R. H. Dissecting the metastatic cascade. Nature Rev. Cancer 4, 448-456 (2004).
84. Pantel, K., Brakenhoff, R. H. & Brandt, B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nature Rev. Cancer 8, 329-340 (2008).
85. Solakoglu, O. et al. Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc. Natl Acad. Sci. USA 99, 2246-2251 (2002).
86. Norton, L., Simon, R., Brereton, H. D. & Bogden, A. E. Predicting the course of Gompertzian growth. Nature 264, 542-545 (1976).
87. Pence, J. C., Kizilbash, A. M., Kerns, B. J., Marks, J. R. & Iglehart, J. D. Proliferation index in various stages of breast cancer determined by Ki-67 immunostaining. J. Surg. Oncol. 48, 11-20 (1991).
88. Bolin, S., Nilsson, E. & Sjodahl, R. Carcinoma of the colon and rectum - growth rate. Ann. Surg. 198, 151-158 (1983).
89. Schmid, H. P., McNeal, J. E. & Stamey, T. A. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 71, 2031-2040 (1993).
90. Cheng, L. et al. Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression. Clin. Cancer Res. 5, 2820-2823 (1999).
91. Cheville, J. C. et al. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer 95, 1028-1036 (2002).
92. Glaves, D., Huben, R. P. & Weiss, L. Haematogenous dissemination of cells from human renal adenocarcinomas. Br. J. Cancer 57, 32-35 (1988).
93. Tarin, D. et al. Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res. 44, 3584-3592 (1984).
94. Hadfield, G. The dormant cancer cell. BMJ 4888, 607-610 (1954).
95. Pantel, K. et al. Differential expression of proliferation- associated molecules in individual micrometastatic carcinoma cells. J. Natl Cancer Inst. 85, 1419-1424 (1993).
96. Minn, A. J. et al. Genes that mediate breast cancer metastasis to lung. Nature 436, 518-524 (2005).
97. Ince, T. A. et al. Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell 12, 160-170 (2007).